In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please cancel claims 12 and 13 without prejudice to their presentation in another application, and amend claims 11, 17, and 20 as follows:

1-10. (canceled).

11. (currently amended) A method for the treatment and/or prevention of metabolic syndrome, whereby a pharmaceutically and pharmacologically effective amount of an angiotensin II type 1 receptor antagonist alone or in combination with a metabolically neutral antihypertensive substance calcium channel antagonist is administered to a subject in need of such treatment or prevention, wherein the angiotensin II type 1 receptor antagonist is of the general formula I:

wherein A is

DOCKET NO.: 133087.09001 (101026-1P US)

PATENT

<u>or</u>

or a pharmaceutically acceptable salt, solvate or stereochemical isomer thereof, or a solvate of such a salt.

- 12-13. (canceled).
- 14. (withdrawn) The method of claim 12, wherein A is I:13.
- 15. (withdrawn) The method of any one of claims 11-14, wherein the metabolically neutral antihypertensive substance is a calcium antagonist.
- 16. (withdrawn) The method of claim 15, wherein the metabolically neutral antihypertensive substance is selected from amlodipine, verapamil, nifedipine, nimodipine, diltiazem, nicardipine, felodipine, emlodipine, ryosidine, lacidipine, niguldipine, niludipine, nisoldipine, nitrendipine, nivaldipine, isradipine, flunarizine, diltiazem, mibefradil, prenylamine, fendiline, gallopamil, verapamil, tiapamil and anipamil, or a pharmaceutically acceptable salt thereof.
- 17. (currently amended) The method of any one of claims 11-14 claim 11, wherein the daily dose of the angiotensin II type 1 receptor antagonist is from about 0.01 mg to about 1000 mg.
- 18. (previously presented) The method of claim 17, wherein the daily dose of the angiotensin II type 1 receptor antagonist is from about 0.1 mg to 750 mg.
- 19. (previously presented) The method of claim 18, wherein the daily dose of the angiotensin II type 1 receptor antagonist is from about 1 mg to 500 mg.
- 20. (currently amended) The method of elaim 13 claim 11, wherein the daily dose of the angiotensin II type 1 receptor antagonist is from about 0.1 mg to about 300 mg per day ealculated as candesartan.